title: Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases.
abstract: OBJECTIVE
  To evaluate the effect of ubenimex capsule on general performance and chemotherapy related toxicity in patients with advanced gastric cancer undergoing chemotherapy.
  
  
  METHODS
  Patients with advanced gastric cancer were randomly divided into two groups: with or without ubenimex. All received the following regimen for 2 cycles: docetaxel 40mg/m(2) intravenous infusion on days 1 and 8, cisplatin 15mg/m(2) and tegafur 600mg/m(2) intravenous infusion from days 1 to 5. Oral ubenimex capsule at 30mg daily was continued for 8 weeks from the start of chemotherapy. Study targets included Karnofsky performance status (KPS), body weight, leukocytes, hemoglobin, variation of several immunologic index prior,during and after chemotherapy.
  
  
  RESULTS
  Sixty-three patients were recruited into this study, 32 randomly entered into the ubenimex capsule and 31 into the control group. KPS score and body weight after chemotherapy were more stable in the treatment group (P <0.05), and myelosuppression, including reduction of leukocytes, hemoglobin and platelets, was milder (P <0.05). T lymphocytes (CD3 +), T assisted- induced lymphocytes (CD3 +, CD4 +), T suppressor and NK cells (CD16 +, CD56 +) all increased after ubenimex capsule intake, while decreasing in the control group (P <0.05).
  
  
  CONCLUSIONS
  Ubenimex capsule could improve general performance and reduce chemotherapy related toxicity in patients with advanced gastric cancer.
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China.
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Xu
authors.forename: Cheng-Guang
authors.initials: CG
authors.lastname: Li
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Jie-Ge
authors.initials: JG
authors.lastname: Huo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002214:Capsules / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000187:drug effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D002214:Capsules; D006454:Hemoglobins; D043823:Taxoids; D005641:Tegafur; D000077143:Docetaxel; D007930:Leucine; C012211:ubenimex; D002945:Cisplatin